Author Correction: Neoadjuvant relatlimab and nivolumab in resectable melanoma.

Autor: Amaria RN; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. rnamaria@mdanderson.org., Postow M; Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA., Burton EM; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Tetzlaff MT; Department of Pathology, The University of California San Francisco, San Francisco, CA, USA., Ross MI; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, US., Torres-Cabala C; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Glitza IC; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Duan F; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Milton DR; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Busam K; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Simpson L; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., McQuade JL; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wong MK; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Gershenwald JE; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, US., Lee JE; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, US., Goepfert RP; Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Keung EZ; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, US., Fisher SB; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, US., Betof-Warner A; Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA., Shoushtari AN; Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA., Callahan M; Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA., Coit D; Department of Surgical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Bartlett EK; Department of Surgical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Bello D; Department of Surgical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Momtaz P; Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA., Nicholas C; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Gu A; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Zhang X; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Korivi BR; Department of Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Patnana M; Department of Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Patel SP; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Diab A; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Lucci A; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, US., Prieto VG; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Davies MA; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Allison JP; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Sharma P; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wargo JA; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, US., Ariyan C; Department of Surgical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Tawbi HA; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jazyk: angličtina
Zdroj: Nature [Nature] 2023 Mar; Vol. 615 (7953), pp. E23.
DOI: 10.1038/s41586-023-05892-1
Databáze: MEDLINE